There’s a specter haunting Wall Street.
It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.
advertisement
Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Ebola: Gilead Sciences antiviral shows promise as new treatment
Next article： Jerome Adams on the need for new antivirals for Covid
Next article： Jerome Adams on the need for new antivirals for Covid
